Companies › vTv Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Metabolic and endocrine; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cadisegliatin Glucokinase activator | GCK | Phase 3 | Diabetes Mellitus, Type 1 | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06334133 | Cadisegliatin | Phase 3 | Diabetes Mellitus, Type 1 | Metabolic and endocrine | Apr 2027 |
Cash of $77m on 2026-09-30; operating cash outflow about $17m a year; runway about 55 months at that burn, to May 2031; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Calcilytix Therapeutics, Inc., a BridgeBio company Medicure Vogenx Fresenius Kabi Renibus Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.